
Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
Keywords: سیتوکروم پی۴۵۰; CRPC; castration-resistant prostate cancer; CYP; cytochrome P450; DHEA; dehydroepiandrosterone; LH-RH; luteinizing-hormone-releasing-hormone; TAK-700; 17,20-Lyase; Prostate cancer; Orteronel;